INOVIO Expects Cash To Fund Operations Into Late 2027 Without Counting VOCERYQ Sales
Launch preparations increased selling and administrative costs, while lower research spending helped reduce total operating expenses.
INOVIO, which develops DNA medicines and is preparing to sell VOCERYQ for recurring airway growths, expects cash to fund operations into the late fourth quarter of 2027 without relying on product sales. The forecast, included in results accompanying Tuesday's SEC filing, extends beyond the planned first-quarter 2027 commercial launch.
Offering Cash Supports The Launch
The forecast incorporates approximately $80.5 million in net proceeds from a completed November public offering, plus $10.9 million from warrant exercises after September 30. INOVIO assumes approximately $21.0 million of operational net cash spending in the fourth quarter of 2026; the projection excludes further fundraising as well as anticipated VOCERYQ sales.
Cash and short-term investments stood at $48.4 million on September 30, versus $58.5 million at the end of 2025. INOVIO had already supplied the September figure as a preliminary estimate Thursday, before the offering proceeds included in Tuesday's outlook.
Research Falls, Launch Costs Rise
Third-quarter operating expenses fell to $19.8 million from $21.2 million a year earlier. Research and development spending declined to $10.6 million from $13.3 million, which INOVIO attributed mainly to reduced outside engineering services for device development and lower employee and consultant compensation.
Selling and administrative spending moved the other way, reaching $9.2 million from $7.9 million. INOVIO attributed the increase to VOCERYQ launch preparations.
The net loss widened to $49.2 million from $45.5 million, primarily because of non-cash changes in warrant values, according to INOVIO. Those charges were $26.9 million, versus $22.5 million a year earlier. Loss per share was $0.50, compared with $0.87, while the weighted-average share count rose to 98,633,024 from 52,168,694.
VOCERYQ's Rollout And Follow-Up Study
The FDA granted VOCERYQ accelerated approval on October 30 to reduce surgery frequency in adults with recurrent respiratory papillomatosis. The disease causes growths in the respiratory tract that can return after removal and obstruct the airway.
Previously called INO-3107, VOCERYQ uses DNA instructions to prompt an immune response against HPV-6 and HPV-11. It is delivered with INOVIO's CELLECTRA device. INOVIO expects orders and shipments to begin approximately 60 days after approval, with full field deployment in the first quarter of 2027. It expects existing inventory and capacity to cover at least the launch's first year through 2027, and has engaged Syneos Health to help recruit and deploy medical and commercial teams.
Continued approval may depend on confirming clinical benefit in further studies. INOVIO expects to send the FDA a draft study protocol by year-end 2026 and align on a final version by mid-2027. It also plans to apply for conditional marketing authorization in Europe before year-end.
President and CEO Jacqueline Shea said INOVIO is "actively seeking partnerships to accelerate the development" of other pipeline candidates. Its DNA-encoded protein programs include potential treatments for hemophilia A, Fabry disease and hypophosphatasia.
INOVIO's cash forecast carries the business beyond its planned launch; revenues from the medicine are expected to begin in 2027 and are excluded from that forecast.
Sources
- 8-K Filing — INOVIO PHARMACEUTICALS, INC. (INO) — SEC EDGAR
- Exhibit ino-93026x8kex991.htm — INOVIO PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR
- Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance — Yahoo Finance
- 8-K filed 2026-11-05 — INOVIO PHARMACEUTICALS, INC. (earlier disclosure) — SEC EDGAR
- 8-K filed 2026-11-02 — INOVIO PHARMACEUTICALS, INC. (earlier disclosure) — SEC EDGAR
